SCHEDULE 13G/A: Goldman Sachs Discloses 9.6% Passive Stake in 4D Molecular Therapeutics

Sentiment:

Beneficial Ownership Statement 10 February 2025 10:28 PM

📋All filings for Goldman Sachs Group INC

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a 9.6% beneficial ownership stake in 4D Molecular Therapeutics, Inc. as of December 31, 2024, through an amended Schedule 13G filing.

Summary

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC jointly reported beneficial ownership of 4,423,435.48 shares of 4D Molecular Therapeutics, Inc. Common Stock.
This ownership represents 9.6% of the issuer's class of securities.
The filing indicates shared voting power over 4,423,418.48 shares and shared dispositive power over 4,423,435.48 shares.
The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
This filing is an Amendment No. 1 to a previously filed Schedule 13G.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing a significant passive ownership stake by a major financial institution. While it doesn't contain positive or negative operational news for the issuer, the presence of a large institutional investor can be viewed as a positive signal of confidence in the issuer's long-term prospects.

Positives

A significant 9.6% beneficial ownership stake in 4D Molecular Therapeutics, Inc. is held by The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, indicating substantial institutional interest.
The filing confirms that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer, suggesting a passive and potentially long-term investment.

Future Outlook

Industry Context

The disclosure of a substantial stake by a major financial institution like Goldman Sachs in 4D Molecular Therapeutics, a company likely in the biotechnology or pharmaceutical sector given its name, reflects ongoing institutional investor interest in life sciences companies. Such investments can signal confidence in the long-term prospects of the sector or specific companies within it, particularly those involved in novel therapeutic development.

Stakeholder Impact

Shareholders: The disclosure of a significant institutional investor holding a 9.6% stake may instill confidence and potentially influence market perception positively.
Management: Awareness of a large passive institutional holder may influence strategic considerations, though the filing explicitly states no intent to influence control.

Key Dates

Date	Description
12/01/2023	Date of superseded Power of Attorney for Goldman Sachs & Co. LLC.
02/09/2024	Date of superseded Power of Attorney for The Goldman Sachs Group, Inc.
07/29/2024	Date of new Power of Attorney for The Goldman Sachs Group, Inc.
10/01/2024	Date of new Power of Attorney for Goldman Sachs & Co. LLC.
12/31/2024	Date of event which requires filing of this statement (measurement date for beneficial ownership).
01/28/2025	Signature date of the Schedule 13G filing.
07/29/2025	Expiration date of the Power of Attorney for The Goldman Sachs Group, Inc.
10/01/2025	Expiration date of the Power of Attorney for Goldman Sachs & Co. LLC.

Recommendation

hold

Keywords

4D Molecular Therapeutics, Goldman Sachs, Schedule 13G, beneficial ownership, institutional investment, common stock, SEC filing, passive stake

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.